First Republic Investment Management Inc. reduced its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 13.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,229 shares of the biopharmaceutical company’s stock after selling 1,116 shares during the quarter. First Republic Investment Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $3,232,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of REGN. Fieldpoint Private Securities LLC purchased a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at $130,000. Sterling Investment Advisors Ltd. increased its position in Regeneron Pharmaceuticals by 11.2% during the 2nd quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock valued at $137,000 after purchasing an additional 28 shares during the period. FNY Partners Fund LP increased its position in Regeneron Pharmaceuticals by 200.0% during the 2nd quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 200 shares during the period. IFP Advisors Inc increased its position in Regeneron Pharmaceuticals by 33.2% during the 2nd quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 96 shares during the period. Finally, Virtu KCG Holdings LLC purchased a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at $206,000. 66.63% of the stock is currently owned by institutional investors and hedge funds.
In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,500 shares of the company’s stock in a transaction dated Thursday, October 5th. The shares were sold at an average price of $475.00, for a total transaction of $712,500.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 10.80% of the stock is currently owned by corporate insiders.
Regeneron Pharmaceuticals Inc (REGN) traded up $6.64 on Tuesday, reaching $382.60. 621,753 shares of the company’s stock traded hands, compared to its average volume of 786,470. The company has a quick ratio of 3.07, a current ratio of 3.63 and a debt-to-equity ratio of 0.12. The company has a market cap of $41,110.00, a PE ratio of 34.75, a P/E/G ratio of 1.48 and a beta of 1.53. Regeneron Pharmaceuticals Inc has a 1-year low of $340.09 and a 1-year high of $543.55.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.83 by $0.16. The business had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.45 billion. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The business’s revenue for the quarter was up 23.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.13 EPS. research analysts forecast that Regeneron Pharmaceuticals Inc will post 13.55 earnings per share for the current fiscal year.
REGN has been the topic of a number of research analyst reports. Raymond James Financial reissued an “outperform” rating and set a $566.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, September 6th. Citigroup reissued a “buy” rating and set a $575.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Thursday, September 7th. Robert W. Baird reissued a “sell” rating and set a $408.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Friday, September 8th. Credit Suisse Group reaffirmed a “buy” rating and issued a $485.00 target price on shares of Regeneron Pharmaceuticals in a research report on Monday, September 11th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $522.00 target price on shares of Regeneron Pharmaceuticals in a research report on Monday, September 11th. Two investment analysts have rated the stock with a sell rating, seventeen have given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $466.14.
ILLEGAL ACTIVITY NOTICE: “Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Shares Sold by First Republic Investment Management Inc.” was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://ledgergazette.com/2018/01/03/first-republic-investment-management-inc-sells-1116-shares-of-regeneron-pharmaceuticals-inc-regn.html.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.